Hinden L - Search Results

1

Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition.

Kogot-Levin A, Riahi Y, Abramovich I, Mosenzon O, Agranovich B, Kadosh L, Ben-Haroush Schyr R, Kleiman D, Hinden L, Cerasi E, Ben-Zvi D, Bernal-Mizrachi E, Tam J, Gottlieb E, Leibowitz G. Kogot-Levin A, et al. Among authors: hinden l. JCI Insight. 2023 Apr 10;8(7):e164296. doi: 10.1172/jci.insight.164296. JCI Insight. 2023. PMID: 36809274 Free PMC article.

2

Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-Induced CKD.

Udi S, Hinden L, Earley B, Drori A, Reuveni N, Hadar R, Cinar R, Nemirovski A, Tam J. Udi S, et al. Among authors: hinden l. J Am Soc Nephrol. 2017 Dec;28(12):3518-3532. doi: 10.1681/ASN.2016101085. Epub 2017 Aug 31. J Am Soc Nephrol. 2017. PMID: 28860163 Free PMC article.

3

Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy.

Hinden L, Udi S, Drori A, Gammal A, Nemirovski A, Hadar R, Baraghithy S, Permyakova A, Geron M, Cohen M, Tsytkin-Kirschenzweig S, Riahi Y, Leibowitz G, Nahmias Y, Priel A, Tam J. Hinden L, et al. J Am Soc Nephrol. 2018 Feb;29(2):434-448. doi: 10.1681/ASN.2017040371. Epub 2017 Oct 13. J Am Soc Nephrol. 2018. PMID: 29030466 Free PMC article.

4

The therapeutic potential of targeting the peripheral endocannabinoid/CB₁ receptor system.

Tam J, Hinden L, Drori A, Udi S, Azar S, Baraghithy S. Tam J, et al. Among authors: hinden l. Eur J Intern Med. 2018 Mar;49:23-29. doi: 10.1016/j.ejim.2018.01.009. Epub 2018 Jan 11. Eur J Intern Med. 2018. PMID: 29336868 Review.

5

Do Endocannabinoids Regulate Glucose Reabsorption in the Kidney?

Hinden L, Tam J. Hinden L, et al. Nephron. 2019;143(1):24-27. doi: 10.1159/000494512. Epub 2019 Jan 11. Nephron. 2019. PMID: 30636250 Review.

6

Dual inhibition of cannabinoid CB₁ receptor and inducible NOS attenuates obesity-induced chronic kidney disease.

Udi S, Hinden L, Ahmad M, Drori A, Iyer MR, Cinar R, Herman-Edelstein M, Tam J. Udi S, et al. Among authors: hinden l. Br J Pharmacol. 2020 Jan;177(1):110-127. doi: 10.1111/bph.14849. Epub 2019 Dec 27. Br J Pharmacol. 2020. PMID: 31454063 Free PMC article.

7

A Novel Indoline Derivative Ameliorates Diabesity-Induced Chronic Kidney Disease by Reducing Metabolic Abnormalities.

Permyakova A, Gammal A, Hinden L, Weitman M, Weinstock M, Tam J. Permyakova A, et al. Among authors: hinden l. Front Endocrinol (Lausanne). 2020 Mar 10;11:91. doi: 10.3389/fendo.2020.00091. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32218769 Free PMC article.

8

Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors.

Kogot-Levin A, Hinden L, Riahi Y, Israeli T, Tirosh B, Cerasi E, Mizrachi EB, Tam J, Mosenzon O, Leibowitz G. Kogot-Levin A, et al. Among authors: hinden l. Cell Rep. 2020 Jul 28;32(4):107954. doi: 10.1016/j.celrep.2020.107954. Cell Rep. 2020. PMID: 32726619 Free PMC article.

9

CB₁R regulates soluble leptin receptor levels via CHOP, contributing to hepatic leptin resistance.

Drori A, Gammal A, Azar S, Hinden L, Hadar R, Wesley D, Nemirovski A, Szanda G, Salton M, Tirosh B, Tam J. Drori A, et al. Among authors: hinden l. Elife. 2020 Nov 19;9:e60771. doi: 10.7554/eLife.60771. Elife. 2020. PMID: 33210603 Free PMC article.

10

Pathogenesis of diabesity-induced kidney disease: role of kidney nutrient sensing.

Hinden L, Kogot-Levin A, Tam J, Leibowitz G. Hinden L, et al. FEBS J. 2022 Feb;289(4):901-921. doi: 10.1111/febs.15790. Epub 2021 Mar 17. FEBS J. 2022. PMID: 33630415 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters